Lymphoma News and Research

RSS
Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.
Research reveals genomic basis of acute erythroid leukemia

Research reveals genomic basis of acute erythroid leukemia

FDA approves treatment for adults with non-radiographic axial spondyloarthritis

FDA approves treatment for adults with non-radiographic axial spondyloarthritis

Heating tumors during CAR T-cell therapy can enhance treatment's success, study suggests

Heating tumors during CAR T-cell therapy can enhance treatment's success, study suggests

City of Hope receives $7.5 million in grant awards to study cutaneous T cell lymphoma

City of Hope receives $7.5 million in grant awards to study cutaneous T cell lymphoma

New drugs on PBS for Parkinson's, MND and Cutaneous T cell lymphoma

New drugs on PBS for Parkinson's, MND and Cutaneous T cell lymphoma

FDA warns two breast implant makers for failure to comply with post-approval study requirements

FDA warns two breast implant makers for failure to comply with post-approval study requirements

Antibody-drug conjugate effectively targets surface protein in childhood neuroblastomas

Antibody-drug conjugate effectively targets surface protein in childhood neuroblastomas

FDA takes action to help reduce risks linked with use of surgical staplers and staples

FDA takes action to help reduce risks linked with use of surgical staplers and staples

A molecular epigenetic marker can predict survival of children with leukemia

A molecular epigenetic marker can predict survival of children with leukemia

Second man cured of HIV

Second man cured of HIV

Study highlights debt and work-related impairments for young adult cancer survivors

Study highlights debt and work-related impairments for young adult cancer survivors

FDA warns Total Thermal Imaging for illegally marketing unapproved thermography device

FDA warns Total Thermal Imaging for illegally marketing unapproved thermography device

New research finds how cancer cells acquire resistance to molecular-targeted drugs

New research finds how cancer cells acquire resistance to molecular-targeted drugs

T-cells play key role in how the body fights follicular lymphoma

T-cells play key role in how the body fights follicular lymphoma

New forms of older anti-cancer agent appear to enhance immune response to fight melanoma

New forms of older anti-cancer agent appear to enhance immune response to fight melanoma

Early marker of cardiac damage triggered by cancer treatment identified

Early marker of cardiac damage triggered by cancer treatment identified

Common herbicide found to increase the risk of Non-Hodgkin Lymphoma

Common herbicide found to increase the risk of Non-Hodgkin Lymphoma

Discovery of weakness in a rare cancer could be exploited with drugs

Discovery of weakness in a rare cancer could be exploited with drugs

Moffitt researchers shed light on how CAR T cells function mechanistically

Moffitt researchers shed light on how CAR T cells function mechanistically

FDA warns doctor for illegally marketing unapproved implantable device

FDA warns doctor for illegally marketing unapproved implantable device

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.